Pooled analysis of pomalidomide for treating patients with multiple myeloma.

Abstract

BACKGROUND:

Patients with refractory or relapsed multiple myeloma are considered to have a very poor prognosis, and new regimens are needed to improve this setting. Pomalidomide is a new immunomodulatory drug with high in vitro potency. Immunomodulatory drugs are hypothesized to act through multiple mechanisms. Here we performed a systemic analysis to evaluate pomalidomide-based chemotherapy (pomalidomide in combination with low-dose dexamethasone) as salvage treatment for patients with refractory and relapsed multiple myeloma.

METHODS:

Clinical studies evaluating the efffectiveness of pomalidomide based regimens on response and safety for patients with refractory and relapsed multiple myeloma were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated.

RESULTS:

For pomalidomide based regimens, 4 clinical studies which including 291 patients with refractory and relapsed multiple myeloma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 41.2% (120/291). Major adverse effects were hematologic toxicity, including grade 1 or 2 anemia, leucopenia and thrombocytopenia with pomalidomide based treatment. No treatment related death occurred.

CONCLUSION:

This pooled analysis suggests that pomalidomide in combination with low-dose dexamethasone is active with good tolerability in treating patients with refractory or relapsed multiple myeloma.

• Authors: Jia-Jia Sun, Chi Zhang, Jun Zhou, Hui-Lin Yang
• Journal: Asian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 16 Issue 8 Pg. 3163-6 ( 2015) ISSN: 2476-762X [Electronic] Thailand
• PMID: 25921115 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Thalidomide
• pomalidomide

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Clinical Trials as Topic
• Drug Resistance, Neoplasm (drug effects)
• Humans
• Meta-Analysis as Topic
• Multiple Myeloma (drug therapy)
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Prognosis
• Salvage Therapy
• Thalidomide (analogs & derivatives, therapeutic use)